Advertisement

Picture BioM Forum Translational Medicine 2018 Würzburg Germany iito 600x60px
Document › Details

Numab Therapeutics AG. (3/28/17). "Press Release: Numab and Ono Pharmaceutical Co., Ltd. Enter into a Research and Option Agreement". Pfäffikon.

Organisations Organisation Numab Therapeutics AG
  Group Numab (Group)
  Organisation 2 Ono Pharmaceutical Co., Ltd. (TSE: 4528)
  Group Ono Pharmaceutical (Group)
Products Product antibody cancer drug
  Product 2 cancer immunotherapy (immuno-oncology, I-O)
Index term Index term Ono Pharmaceutical–Numab: antibody cancer drug, 201703– research + option agreem up to CHF258m + royalties for multi-specific antibody
Persons Person Middendorp, Oliver (Numab 201703 CBO + Co-CEO of Numab Therapeutics AG)
  Person 2 Habashita, Hiromu (Ono Pharmaceutical 201703 Corp Officer + Executive Director Discovery + Research)
     


Numab to receive up to CHF 258 million plus tiered royalties on sales


Numab Therapeutics AG (“Numab”) today announced a research and option agreement with Ono Pharmaceutical Co., Ltd. (“Ono”) for the identification of a multi-specific antibody candidate for development in immuno-oncology.

Under the agreement, Ono will obtain an option to acquire intellectual property rights to, and exclusive rights to develop and commercialize, the selected lead compound to be generated through this collaboration, which will exploit one of Ono’s novel therapeutic approaches in immuno-oncology. In exchange Numab will receive research funding and up to CHF 258 million in upfront and milestone payments plus tiered single to double digit royalties on sales.

Oliver Middendorp co-CEO of Numab, said: “We are extremely pleased to start our collaboration with Ono, a company with a track record of scientific excellence and innovation, and that most recently made its mark by launching a new era in cancer treatment with the development of the first anti-PD-1 antibody, Nivolumab/Opdivo.”

Hiromu Habashita, Corporate Officer, and Executive Director of Discovery & Research of Ono, said: “We highly value the capabilities of Numab’s multi-specific antibody platform. It is robust, and optimized to reproducibly yield product candidates with outstanding binding properties. We believe it is ideally suited to fuel our immuno-oncology drug discovery and consequently a multi-specific antibody to be generated through this collaboration will provide hope to sufferers of cancer.”


About Numab

Founded in 2011, Numab develops a proprietary pipeline of multi-specific biotherapeutics in immuno-oncology and immunology, and has a number of discovery partnerships with pharmaceutical companies. Numab’s plug-and-play multi-specifics platform allows for a highly rational and reproducible process that rapidly yields promising clinical candidates with new mechanisms of action, superior efficacy and a favorable safety profile. For further information, visit www.numab.com.

About Ono Pharmaceutical Co., Ltd.

Ono Pharmaceutical Co., Ltd., headquartered in Osaka, Japan, is an R&D-oriented pharmaceutical company committed to create innovative medicines in specific areas. It focuses especially on the oncology and diabetes areas. For more information, please visit the company’s website at http://www.ono.co.jp/eng/index.html.


MEDIA CONTACTS

Numab Therapeutics AG
Oliver Middendorp
CBO & co-CEO
o.middendorp@numab.com

Capricorn One
Hans Herklots
+41 79 598 7149
capricorn1@bluewin.ch

   
Record changed: 2017-04-19

Advertisement

Picture BioM Forum Translational Medicine 2018 Würzburg Germany iito 600x60px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture EBD Group BIO-Europe 2018 Copenhagen Denmark Partnering Open 600x60px




» top